)
Visual
test
Dicot
Dicot (DICOT) investor relations material
Dicot Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary23 Oct, 2025
Executive summary
Phase 2a clinical study for LIB-01 completed, showing long-lasting improvement in erectile function and favorable safety profile; effect sustained for eight weeks after a three-day treatment.
Company preparing for Phase 2b study, including tablet development and IND submission to FDA.
LIB-01 highlighted by Oppenheimer as a promising candidate in the longevity and erectile dysfunction space.
Financial highlights
Net sales were MSEK 0.0 for both Q3 and the nine-month period, unchanged year-over-year.
Result after financial items for Q3 was MSEK -16.1 (vs. -10.2 last year); for Jan–Sep, MSEK -63.4 (vs. -37.0 last year).
Earnings per share for Q3 was SEK -0.01 (unchanged); Jan–Sep was SEK -0.03 (improved from -0.04).
Operating expenses for Q3 were SEK 16.6 million, up from SEK 10.2 million last year but down from SEK 25.0 million in the previous quarter.
Cash and cash equivalents at quarter-end were SEK 90.0 million (down from SEK 130.4 million last year).
Outlook and guidance
Cash balance intended to finance Phase 2b study, manufacturing scale-up, and preparations for Phase 3.
Additional funding will be needed before Phase 2b, potentially through equity, out-licensing, or both.
Ongoing evaluation of expanding indications, including metabolic diseases.
Detail Phase 2b funding strategy
What are the next steps for industrial partnerships?
Update on metabolic disease research strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebWEX
Q4 2025 revenue and EPS grew strongly, with 2026 guidance projecting continued momentum. - 5 FebCLFD
FY25 sales rose 20% to $150.1M, with improved margins and strong growth outlook for FY26. - 5 FebMAA
Q4 and 2025 results met expectations; 2026 outlook sees modest growth and easing supply. - 5 FebGL
Earnings and premium growth drive higher 2026 guidance and continued share repurchases. - 5 FebABX
Record earnings, strong cash flow, and North America gold IPO plans drive 2025 results. - 5 FebDG
Record free cash flow and broad-based earnings growth drive strong 2025 results and positive 2026 outlook. - 5 FebMOD
Q3 FY26 sales up 31%, strong data center growth, pension charge led to net loss, major spin-off announced. - 5 FebAPOLLOTYRE
Record revenue, profit growth, major expansion, and improved financial metrics in Q3 FY26. - 5 FebCMI
Record 2025 results, $458M Accelera charges, and 2026 growth led by data center power. - 5 FebHP
EBITDA $230M, $1.02B revenue, net loss $97M, $260M debt repaid, strong tech rollout.
Next Dicot earnings date
Q4 202518 Feb, 2026
Dicot
Next Dicot earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dicot AB is a pharmaceutical company focused on the development of lifestyle drugs, primarily addressing sexual health issues such as erectile dysfunction and premature ejaculation. Founded in 2021, Dicot conducts drug discovery and development aimed at improving quality of life for patients with these conditions. The company's main research involves the drug candidate LIB-01, which is in the early stages of clinical trials. Dicot AB is a private entity and maintains active operations, contributing to the healthcare and drug development sectors. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage